SNPX
Price:
$2.6
Market Cap:
$3.52M
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is...[Read more]
Industry
Biotechnology
IPO Date
2020-12-08
Stock Exchange
NASDAQ
Ticker
SNPX
According to Synaptogenix, Inc.’s latest financial reports and current stock price. The company's current ROE is -41.97%. This represents a change of 202.09% compared to the average of -13.89% of the last 4 quarters.
The mean historical ROE of Synaptogenix, Inc. over the last ten years is -80.23%. The current -41.97% ROE has changed -47.68% with respect to the historical average. Over the past ten years (40 quarters), SNPX's ROE was at its highest in in the December 2022 quarter at 12.66%. The ROE was at its lowest in in the December 2020 quarter at -57.68%.
Average
-80.23%
Median
-39.58%
Minimum
-277.32%
Maximum
-15.41%
Discovering the peaks and valleys of Synaptogenix, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 227.36%
Maximum Annual ROE = -15.41%
Minimum Annual Increase = -86.44%
Minimum Annual ROE = -277.32%
Year | ROE | Change |
---|---|---|
2023 | -24.80% | 60.93% |
2022 | -15.41% | -59.00% |
2021 | -37.59% | -86.44% |
2020 | -277.32% | 227.36% |
2019 | -84.71% | 103.83% |
The current ROE of Synaptogenix, Inc. (SNPX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-25.93%
5-year avg
-87.97%
10-year avg
-80.23%
Synaptogenix, Inc.’s ROE is less than Annovis Bio, Inc. (874.76%), less than Cyclo Therapeutics, Inc. (749.85%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than INmune Bio, Inc. (-115.51%), less than Alzamend Neuro, Inc. (276.87%),
Company | ROE | Market cap |
---|---|---|
874.76% | $91.75M | |
749.85% | $21.00M | |
664.92% | $38.12M | |
-115.51% | $107.98M | |
276.87% | $5.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Synaptogenix, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Synaptogenix, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Synaptogenix, Inc.'s ROE?
How is the ROE calculated for Synaptogenix, Inc. (SNPX)?
What is the highest ROE for Synaptogenix, Inc. (SNPX)?
What is the 3-year average ROE for Synaptogenix, Inc. (SNPX)?
What is the 5-year average ROE for Synaptogenix, Inc. (SNPX)?
How does the current ROE for Synaptogenix, Inc. (SNPX) compare to its historical average?